

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

CHANGE OF CHIEF FINANCIAL OFFICER, COMPANY SECRETARY AND ALTERNATE AUTHORISED REPRESENTATIVE

The board of directors (the “**Board**”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”) announces that Mr. Chow Hing Yeung (“**Mr. Chow**”) has resigned as Chief Financial Officer, Company Secretary and Alternate Authorised Representative of the Company with effect from 13 May 2013 in order to pursue other career opportunities. Mr. Chow has confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited or/and the shareholders of the Company in relation to his resignation.

The Board is pleased to announce that Mr. Chan Ka Kit (“**Mr. Chan**”) has been appointed as Chief Financial Officer, Company Secretary and Alternate Authorised Representative of the Company with effect from 13 May 2013. Mr. Chan is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Chan obtained a Bachelor’s degree of Art in Accountancy from the City University of Hong Kong. He has more than 13 years of experience in areas of accounting and taxation.

The Board would like to take this opportunity to express its sincere appreciation to Mr. Chow for his valuable contribution to the Company during his tenure of services and wish him every success and also welcome Mr. Chan for his new appointment.

By order of the Board

Wu Qin

Chairman

Hong Kong, 10 May 2013

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.